Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.77
BABY's Cash to Debt is ranked lower than
54% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. BABY: 1.77 )
Ranked among companies with meaningful Cash to Debt only.
BABY' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: No Debt Max: No Debt
Current: 1.77
Equity to Asset 0.65
BABY's Equity to Asset is ranked higher than
53% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. BABY: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
BABY' s Equity to Asset Range Over the Past 10 Years
Min: -1.71  Med: 0.82 Max: 0.94
Current: 0.65
-1.71
0.94
Interest Coverage 78.61
BABY's Interest Coverage is ranked lower than
51% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 97.42 vs. BABY: 78.61 )
Ranked among companies with meaningful Interest Coverage only.
BABY' s Interest Coverage Range Over the Past 10 Years
Min: 10.45  Med: 100.22 Max: N/A
Current: 78.61
F-Score: 7
Z-Score: 4.76
M-Score: -3.29
WACC vs ROIC
8.38%
13.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.47
BABY's Operating margin (%) is ranked higher than
80% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. BABY: 14.47 )
Ranked among companies with meaningful Operating margin (%) only.
BABY' s Operating margin (%) Range Over the Past 10 Years
Min: -4.44  Med: 11.48 Max: 15.75
Current: 14.47
-4.44
15.75
Net-margin (%) 11.15
BABY's Net-margin (%) is ranked higher than
78% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. BABY: 11.15 )
Ranked among companies with meaningful Net-margin (%) only.
BABY' s Net-margin (%) Range Over the Past 10 Years
Min: -4.8  Med: 7.55 Max: 11.15
Current: 11.15
-4.8
11.15
ROE (%) 10.62
BABY's ROE (%) is ranked higher than
72% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. BABY: 10.62 )
Ranked among companies with meaningful ROE (%) only.
BABY' s ROE (%) Range Over the Past 10 Years
Min: -4.28  Med: 8.52 Max: 10.62
Current: 10.62
-4.28
10.62
ROA (%) 8.20
BABY's ROA (%) is ranked higher than
79% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 0.07 vs. BABY: 8.20 )
Ranked among companies with meaningful ROA (%) only.
BABY' s ROA (%) Range Over the Past 10 Years
Min: -3.46  Med: 5.94 Max: 8.3
Current: 8.2
-3.46
8.3
ROC (Joel Greenblatt) (%) 57.61
BABY's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. BABY: 57.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BABY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -12.53  Med: 41.37 Max: 57.61
Current: 57.61
-12.53
57.61
Revenue Growth (3Y)(%) 1.10
BABY's Revenue Growth (3Y)(%) is ranked lower than
59% of the 224 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. BABY: 1.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BABY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.9  Med: 10.65 Max: 38.3
Current: 1.1
-61.9
38.3
EBITDA Growth (3Y)(%) 13.10
BABY's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. BABY: 13.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BABY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -88.5  Med: 22.8 Max: 863.2
Current: 13.1
-88.5
863.2
EPS Growth (3Y)(%) 19.80
BABY's EPS Growth (3Y)(%) is ranked higher than
73% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. BABY: 19.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BABY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.8  Med: -1.6 Max: 106.2
Current: 19.8
-52.8
106.2
GuruFocus has detected 1 Warning Sign with Natus Medical Inc $BABY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BABY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BABY Guru Trades in Q1 2016

Diamond Hill Capital 591,256 sh (+20.51%)
Paul Tudor Jones Sold Out
Ken Fisher 589,433 sh (-0.98%)
Joel Greenblatt 84,563 sh (-53.26%)
Jim Simons 56,945 sh (-58.81%)
» More
Q2 2016

BABY Guru Trades in Q2 2016

Robert Olstein 57,025 sh (New)
Steven Cohen 622,600 sh (New)
Joel Greenblatt 280,046 sh (+231.17%)
Ken Fisher 589,798 sh (+0.06%)
Diamond Hill Capital 591,256 sh (unchged)
Jim Simons Sold Out
» More
Q3 2016

BABY Guru Trades in Q3 2016

Columbia Wanger 265,000 sh (New)
Jim Simons 13,200 sh (New)
Ken Fisher 611,816 sh (+3.73%)
Steven Cohen Sold Out
Diamond Hill Capital 589,744 sh (-0.26%)
Robert Olstein 55,850 sh (-2.06%)
Joel Greenblatt 142,710 sh (-49.04%)
» More
Q4 2016

BABY Guru Trades in Q4 2016

Paul Tudor Jones 16,520 sh (New)
Steven Cohen 74,900 sh (New)
Jim Simons 45,800 sh (+246.97%)
Columbia Wanger 590,825 sh (+122.95%)
Robert Olstein 77,795 sh (+39.29%)
Joel Greenblatt 147,129 sh (+3.10%)
Diamond Hill Capital 589,551 sh (-0.03%)
Ken Fisher 610,049 sh (-0.29%)
» More
» Details

Insider Trades

Latest Guru Trades with BABY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:CNMD, OTCPK:IOBCF, NAS:SPNC, NAS:INGN, NYSE:ITGR, NAS:VASC, NAS:CSII, NAS:CYNO, NAS:MDXG, NAS:KTWO, NAS:OFIX, NYSE:CRY, OTCPK:NHNKY, NAS:GNMK, NAS:ARAY, OTCPK:MZRTF, NYSE:IVC, NAS:XENT, NAS:AXGN, NAS:EXAC » details
Traded in other countries:NM4.Germany,
Natus Medical Inc provides newborn care & neurology healthcare products & services used for screening, diagnosis, detection, treatment, monitoring & tracking of medical ailments in newborn care, epilepsy, sleep disorders, and balance & mobility disorders.

Natus Medical Inc was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. The Company is a provider of newborn care and neurology healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The Company offers two product families: Neurology and Newborn Care. Neurology includes products for diagnostic electroencephalography (EEG), electromyography (EMG), diagnostic sleep analysis or polysomnography (PSG), intra-operative monitoring (IOM), and transcranial doppler ultrasound technology. Newborn Care includes products for newborn care including hearing screening, brain injury, thermoregulation, jaundice management, and various disposable products, as well as products for diagnostic hearing assessment for children through adult populations, and products to diagnose and assist in treating balance and mobility disorders. The Company is subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements.

Top Ranked Articles about Natus Medical Inc

Weekly CEO Buys Highlight Insiders invest in Natus, OPKO, Mobile Mini, S&T Bancorp, Investors Real Estate
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight Largest insider buys for Valvoline, Natus, OPKO and Guess
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purhases is illustrated in the chart below: Read more...
Natus Medical CEO Acquires Shares in Company Insider purchases 10,000 shares
James Hawkins (Insider Trades), president and CEO of Natus Medical Inc. (BABY), acquired 10,000 shares in the company on Sept. 28. The price per share was $38.48 for a total transaction of $384,800. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 29.38
BABY's P/E(ttm) is ranked lower than
55% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.50 vs. BABY: 29.38 )
Ranked among companies with meaningful P/E(ttm) only.
BABY' s P/E(ttm) Range Over the Past 10 Years
Min: 11.26  Med: 35.43 Max: 699.33
Current: 29.38
11.26
699.33
Forward P/E 21.55
BABY's Forward P/E is ranked higher than
61% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.92 vs. BABY: 21.55 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 29.38
BABY's PE(NRI) is ranked lower than
55% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 25.48 vs. BABY: 29.38 )
Ranked among companies with meaningful PE(NRI) only.
BABY' s PE(NRI) Range Over the Past 10 Years
Min: 11.26  Med: 35.43 Max: 699.33
Current: 29.38
11.26
699.33
Price/Owner Earnings (ttm) 22.63
BABY's Price/Owner Earnings (ttm) is ranked higher than
64% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 30.29 vs. BABY: 22.63 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BABY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 18.79  Med: 40.95 Max: 8415
Current: 22.63
18.79
8415
P/B 2.98
BABY's P/B is ranked higher than
53% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. BABY: 2.98 )
Ranked among companies with meaningful P/B only.
BABY' s P/B Range Over the Past 10 Years
Min: 0.79  Med: 2.46 Max: 5.69
Current: 2.98
0.79
5.69
P/S 3.27
BABY's P/S is ranked higher than
50% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.29 vs. BABY: 3.27 )
Ranked among companies with meaningful P/S only.
BABY' s P/S Range Over the Past 10 Years
Min: 0.95  Med: 2.53 Max: 7.43
Current: 3.27
0.95
7.43
PFCF 18.07
BABY's PFCF is ranked higher than
69% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. BABY: 18.07 )
Ranked among companies with meaningful PFCF only.
BABY' s PFCF Range Over the Past 10 Years
Min: 12.62  Med: 32.07 Max: 490.59
Current: 18.07
12.62
490.59
POCF 17.22
BABY's POCF is ranked higher than
56% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 18.12 vs. BABY: 17.22 )
Ranked among companies with meaningful POCF only.
BABY' s POCF Range Over the Past 10 Years
Min: 10.17  Med: 25.71 Max: 106.24
Current: 17.22
10.17
106.24
EV-to-EBIT 20.65
BABY's EV-to-EBIT is ranked higher than
51% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.48 vs. BABY: 20.65 )
Ranked among companies with meaningful EV-to-EBIT only.
BABY' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.3  Med: 23.1 Max: 409.7
Current: 20.65
-29.3
409.7
EV-to-EBITDA 15.81
BABY's EV-to-EBITDA is ranked higher than
50% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 15.79 vs. BABY: 15.81 )
Ranked among companies with meaningful EV-to-EBITDA only.
BABY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -82.2  Med: 17 Max: 5595.8
Current: 15.81
-82.2
5595.8
PEG 0.15
BABY's PEG is ranked higher than
97% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. BABY: 0.15 )
Ranked among companies with meaningful PEG only.
BABY' s PEG Range Over the Past 10 Years
Min: 0.15  Med: 1.17 Max: 2.38
Current: 0.15
0.15
2.38
Shiller P/E 62.17
BABY's Shiller P/E is ranked lower than
65% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 49.62 vs. BABY: 62.17 )
Ranked among companies with meaningful Shiller P/E only.
BABY' s Shiller P/E Range Over the Past 10 Years
Min: 43.71  Med: 80.87 Max: 115
Current: 62.17
43.71
115
Current Ratio 5.08
BABY's Current Ratio is ranked higher than
79% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. BABY: 5.08 )
Ranked among companies with meaningful Current Ratio only.
BABY' s Current Ratio Range Over the Past 10 Years
Min: 1.41  Med: 3.17 Max: 16.01
Current: 5.08
1.41
16.01
Quick Ratio 4.46
BABY's Quick Ratio is ranked higher than
79% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. BABY: 4.46 )
Ranked among companies with meaningful Quick Ratio only.
BABY' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 2.57 Max: 15.09
Current: 4.46
1
15.09
Days Inventory 118.78
BABY's Days Inventory is ranked higher than
54% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 130.88 vs. BABY: 118.78 )
Ranked among companies with meaningful Days Inventory only.
BABY' s Days Inventory Range Over the Past 10 Years
Min: 104.01  Med: 123.48 Max: 132.84
Current: 118.78
104.01
132.84
Days Sales Outstanding 82.81
BABY's Days Sales Outstanding is ranked lower than
65% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 66.78 vs. BABY: 82.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
BABY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 81.74  Med: 86.98 Max: 112.34
Current: 82.81
81.74
112.34
Days Payable 46.45
BABY's Days Payable is ranked lower than
59% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. BABY: 46.45 )
Ranked among companies with meaningful Days Payable only.
BABY' s Days Payable Range Over the Past 10 Years
Min: 44.18  Med: 67.82 Max: 92.09
Current: 46.45
44.18
92.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.60
BABY's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. BABY: -1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BABY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -185.4  Med: -3.4 Max: -1.6
Current: -1.6
-185.4
-1.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 68.91
BABY's Price/Net Cash is ranked lower than
89% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. BABY: 68.91 )
Ranked among companies with meaningful Price/Net Cash only.
BABY' s Price/Net Cash Range Over the Past 10 Years
Min: 1.62  Med: 4.71 Max: 69.73
Current: 68.91
1.62
69.73
Price/Net Current Asset Value 7.07
BABY's Price/Net Current Asset Value is ranked lower than
53% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 6.59 vs. BABY: 7.07 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BABY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.27  Med: 6.49 Max: 12.49
Current: 7.07
1.27
12.49
Price/Tangible Book 5.49
BABY's Price/Tangible Book is ranked lower than
61% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 4.24 vs. BABY: 5.49 )
Ranked among companies with meaningful Price/Tangible Book only.
BABY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.19  Med: 4.55 Max: 64.5
Current: 5.49
1.19
64.5
Price/Projected FCF 1.85
BABY's Price/Projected FCF is ranked higher than
58% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. BABY: 1.85 )
Ranked among companies with meaningful Price/Projected FCF only.
BABY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.8  Med: 1.5 Max: 4.31
Current: 1.85
0.8
4.31
Price/Median PS Value 1.30
BABY's Price/Median PS Value is ranked lower than
71% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. BABY: 1.30 )
Ranked among companies with meaningful Price/Median PS Value only.
BABY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 0.97 Max: 2.77
Current: 1.3
0.15
2.77
Price/Peter Lynch Fair Value 8.69
BABY's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 1.74 vs. BABY: 8.69 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BABY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0  Med: 1.43 Max: 8.8
Current: 8.69
0
8.8
Price/Graham Number 2.68
BABY's Price/Graham Number is ranked lower than
60% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. BABY: 2.68 )
Ranked among companies with meaningful Price/Graham Number only.
BABY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.71  Med: 3.1 Max: 11.38
Current: 2.68
1.71
11.38
Earnings Yield (Greenblatt) (%) 4.81
BABY's Earnings Yield (Greenblatt) (%) is ranked higher than
76% of the 337 Companies
in the Global Medical Devices industry.

( Industry Median: -0.30 vs. BABY: 4.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BABY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 4.2 Max: 20
Current: 4.81
0.2
20
Forward Rate of Return (Yacktman) (%) 12.61
BABY's Forward Rate of Return (Yacktman) (%) is ranked higher than
62% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 8.88 vs. BABY: 12.61 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BABY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1.5  Med: 2.8 Max: 75
Current: 12.61
-1.5
75

More Statistics

Revenue (TTM) (Mil) $381.9
EPS (TTM) $ 1.29
Beta0.85
Short Percentage of Float8.15%
52-Week Range $29.54 - 44.39
Shares Outstanding (Mil)32.91

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 503 523
EPS ($) 1.77 2.23
EPS w/o NRI ($) 1.77 2.23
EPS Growth Rate
(3Y to 5Y Estimate)
22.00%
Dividends Per Share ($)
» More Articles for BABY

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight Dec 27 2016 
Weekly CEO Buys Highlight Oct 31 2016 
Weekly CEO Buys Highlight Oct 03 2016 
Natus Medical CEO Acquires Shares in Company Sep 29 2016 
Robert Olstein's Best Performing Investments Include eBay Aug 14 2016 
Diamond Hill Small Cap Fund Q4 2014 Commentary Mar 17 2015 
Diamond Hill Small Cap Fund Third Quarter Letter Oct 25 2014 
Diamond Hill Capital Comments on Natus Medical Inc Oct 17 2014 
Diamond Hill Small Cap Fund Third Quarter 2014 Commentary Oct 17 2014 
Diamond Hill Capital Comments on Natus Medical Inc Jun 26 2014 

More From Other Websites
IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Natus... Feb 21 2017
BABY INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Feb 21 2017
IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Natus... Feb 20 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Natus... Feb 20 2017
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Natus... Feb 20 2017
NATUS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS... Feb 17 2017
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Natus... Feb 17 2017
Lifshitz & Miller LLP Announces Investigation of Centrue Financial Corporation, Motorola Solutions,... Feb 17 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Feb 16 2017
Natus Medical Investor Deadline Reminder: Hagens Berman Reminds Investors in Natus Medical of the... Feb 16 2017
IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Natus... Feb 16 2017
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Natus... Feb 15 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Feb 15 2017
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Natus... Feb 14 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Natus Medical Incorporated of a... Feb 14 2017
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Natus... Feb 13 2017
Johnson & Weaver, LLP Announces Securities Class Action Lawsuits against RH, Natus Medical... Feb 13 2017
IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Natus... Feb 10 2017
Pawar Law Group Announces that a Securities Class Action Lawsuit has been filed Against Natus... Feb 10 2017
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Natus... Feb 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)